Aranesp and Haematotoxicity - a phase IV clinical study of FDA data

Summary:

Haematotoxicity is reported as a side effect among people who take Aranesp (darbepoetin alfa), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Folic Acid, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Haematotoxicity when taking Aranesp. It is created by eHealthMe based on reports of 54,218 people who have side effects when taking Aranesp from the FDA, and is updated regularly.

What is Aranesp?

Aranesp has active ingredients of darbepoetin alfa. It is often used in anemia. eHealthMe is studying from 54,331 Aranesp users. Check the latest studies of Aranesp.

What is Haematotoxicity?

Haematotoxicity (toxins that destroy red blood cells) is found to be associated with 344 drugs and 829 conditions by eHealthMe. Check the latest studies of Haematotoxicity.

On Jul, 20, 2026

54,218 people reported to have side effects when taking Aranesp.
Among them, 15 people (0.03%) have Haematotoxicity.

Among these 15 people:

How long have people been on Aranesp when they have Haematotoxicity? *

What is the gender of people who have Haematotoxicity when taking Aranesp? *

female: 40 %
male: 60 %

What is the age of people who have Haematotoxicity when taking Aranesp? *

What are other drugs people take besides Aranesp? *

What are other side effects people have besides Haematotoxicity? *

Thrombocytopenia (decrease of platelets in blood): 8 people, 53.33%
Anaemia (lack of blood): 5 people, 33.33%
Heart Rate Increased: 4 people, 26.67%
Hypokalemia (low potassium): 4 people, 26.67%
Diarrhea: 3 people, 20.00%
Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 3 people, 20.00%
Fatigue (feeling of tiredness): 3 people, 20.00%
Blood Urea Increased: 3 people, 20.00%
Gastroenteritis (inflammation of stomach and intestine): 3 people, 20.00%
Breathing - Slowed Or Stopped: 3 people, 20.00%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 4 people, 26.67%
Mesothelioma (rare type of cancer that occurs in the thin layer of cells lining the body's internal organs, known as the mesothelium): 3 people, 20.00%
Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 2 people, 13.33%
Depression: 1 person, 6.67%
Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 1 person, 6.67%
Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 1 person, 6.67%
Cancer Pain: 1 person, 6.67%
Breast Cancer Stage Iv: 1 person, 6.67%
Anaemia (lack of blood): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Aranesp and have Haematotoxicity?

- Check whether Haematotoxicity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Aranesp:

Aranesp (54,331 reports)

Haematotoxicity treatments and more:

Haematotoxicity (8,984 reports)

Browse all side effects of Aranesp:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Haematotoxicity:

Haematotoxicity (344 drugs)

Browse all the conditions that are associated with Haematotoxicity:

Haematotoxicity (829 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on darbepoetin alfa (the active ingredients of Aranesp) and Aranesp (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.